The Niche’s recommended Weekly Reads on stem cell research and regenerative medicine.
People are the real driving force in the stem cell and regenerative medicine field including my colleague Jan Nolta here at UC Davis. She is the Director of our Stem Cell Program. There’s also news about Stanford’s stem cell Director Irv Weissman. Jan Nolta receives award Jan’s lab is prolific and in many ways is […]
Weekly reads: Jan Nolta recognition, new director after Irv, FDA guidance Read More »
I recently wrote about stem cell-related ideas for anti-aging and even cheating death, but there are of course other approaches including drugs like metformin. A new article outlines a massive research funding plan to tackle aging. Let’s start with that. Recommend reads including anti-aging Saudi Arabia plans to spend $1 billion a year discovering treatments to
Weekly reads: $1B Saudi anti-aging push, OCT4 necklace, cancer trial wows, coffee brain Read More »
David Weinberg over at Science-Based Medicine has his part two of a deep dive into the so-called SCOTS trial, which is a non-traditional pay-for-play study. I highly recommend it. SCOTS trial under the magnifying glass In this piece, Weinberg provides interesting background on the two people running SCOTS. I’ve had many concerns about the SCOTS
Recommended reads: engineered niche, ALS, SCOTS trial, human genome “done” Read More »
The big news of the week was a $3.6 million settlement by a stem cell clinic, StemGenex, and one of its doctors in a class-action suit. I covered this StemGenex settlement and so did Michael Hiltzik of the LA Times and Paul Schloesser at Endpoints. I’d say this was good news for the stem cell field
Stem cell weekly reads: Jamie Thomson, Lamin B1, CRISPR Read More »
The idea of stem cells outright curing diseases is exciting and has powerful appeal, but media need to be careful about using the word cure in headlines and articles as we saw this week related to a possible HIV Cure. HIV cure via stem cells and chemo? The big news of the week was that
Weekly reads: possible rare HIV cure, stem cell chicken, FDA commish Read More »
Is 2022 going to be any better than 2020 or 2021 when it comes to things in general or for biomedical science? Related to the pandemic? It’s too soon to say but if I had to guess right now I’d venture an optimistic view that overall it’s going to be somewhat better by the end
Weekly science reads: senescence, alt CRISPR, sickle cell update Read More »
Happy New Year and get ready for another 364 more days of stem cell excitement and craziness in 2022. In the next day or two I’ll post my predictions for this new year. Recommended reads EO Wilson obit by Carl Zimmer in NYT. Who’s the next EO Wilson or someone like him with such big impact these
Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson Read More »
Part of being a grad student is dealing with technologies related to your projects and their limitations. Sometimes I feel old when I remember the way we used to have to do things in the lab. As a grad student, I manually poured, ran, and read giant sequencing gels. Back then, gene synthesis of a
Weekly reads: grad student life, cell barcoding, diabetes trial, more Read More »
What are your favorite cells? The stem variety? T-cells? I have a hard time choosing just one favorite. The first news item I feature talks new imaging methods to see deep inside any cells. Have a favorite organelle? The secret lives of cells — as never seen before, Nature. This news item covers newer imaging techniques
Recommended reads: secrets of cells, T-cells, CRISPR Read More »
The other day I was talking with some folks about stem cell policy on Zoom, which was great, but one phrase from them jumped out at me and gave me a laugh. “Joe Rogan is the Gwyneth Paltrow for bros.” It also just rings true to me. Some readers of The Niche may remember that
Weekly reads: Joe Rogan, stem cell, diet, clinics, more Read More »